Have any questions? 706-721-6582 or cts@augusta.edu
- CDX1140-01: A Phase 1 Study of CDX-1140, a Fully Human Agonist anti-CD40 Monoclonal Antibody, as Monotherapy or in Combination in Patients with Advanced Malignancies
Clinical Trial
CDX1140-01: A Phase 1 Study of CDX-1140, a Fully Human Agonist anti-CD40 Monoclonal Antibody, as Monotherapy or in Combination in Patients with Advanced Malignancies
The purpose of this study is to test the safety and tolerability of study drug CDX-1140 alone and in combination with another study drug, CDX-301, in patients with solid tumors or lymphomas. It is hoped the combination of the study treatments CDX-1140 and CDX-301 will enhance anti-tumor immune responses. Subjects who have received prior standard therapy for their tumor type or lymphoma and show that their disease (cancer) has returned or not responded to standard treatment will be enrolled. Subjects will continue receiving study treatment unless their cancer returns or intolerance of the study treatment.
- Digestive System
- Endocrine System
- Female Reproductive System
- Integumentary System
- Lymphatic System
- Nervous System
- Respiratory System
- Urinary System
- Immunotherapy
- Lymphoma
- Solid Tumor
Eligibility Criteria
- Brief inclusion criteria: Age 18 and older; Have one of the following cancers that has returned or progressed: melanoma, bladder/urothelial, non-small cell lung cancer, pancreatic, breast, colorectal, gastric, esophageal, renal (kidney), hepatic (liver), ovarian, fallopian or primary peritoneal cancer; head and neck, cholangiocarcinoma; B-cell lymphoma; Life expectancy of at least 3 months; Not pregnant. Brief exclusion criteria: Prior treatment with T-cell or other cell-based therapies within 12 weeks; Not participating in another study; HIV infection or Hepatitis B or C infection.
RESEARCH. INNOVATION. DISCOVERY.